HomeCategoryNews - Verséa

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/women-in-science-l.jpg?resize=1200%2C640&ssl=1

Verséa Discovery successfully ran its first validation test assays at the UCSD Biomedical Lab using its proprietary VCX™ Discovery Platform   The cellular based platform VCX™ Discovery Platform follows a proprietary process developed by Verséa Discovery. Through machine learning, the system links highly specific cellular functions (focused on mitochondrial biology and second messenger signaling) to...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/03/vision-concept_800-e1648064890754.jpg?resize=800%2C464&ssl=1

A recently published peer-reviewed scientific article “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma” has provided insight into unique therapeutic potential of Cannabinol (CBN) for glaucoma treatment   The article, published in a leading international journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease) (LINK to the article)...

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/an-aerial-shot-of-people-standing-together-to-form-the-outline-of-the-novel-coronavirus-m.jpg?resize=800%2C400&ssl=1

Researchers screen rapid-detection COVID-19 tests for sensitivity/specificity, limit of detection, and time to results ANN ARBOR, MI, and VANCOUVER, BC—February 10, 2021—After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified five direct (antigen/RNA) tests for detection of acute infection and six indirect (antibody) tests for...